Literature DB >> 10333711

Clinicopathologic characteristics of mucinous gastric adenocarcinoma.

W J Hyung1, S H Noh, D W Shin, C H Yoo, C B Kim, J S Min, K S Lee.   

Abstract

There has been considerable controversy over the prognosis of mucinous gastric adenocarcinoma (MGC). In this study we analyzed the clinicopathologic differences between MGC and non-mucinous gastric carcinoma (NMGC). In addition, the relationship between mucin content and other clinicopathologic variables, including prognosis in MGC, was also investigated. We reviewed 2118 patients with pathologically-confirmed gastric cancer who underwent gastrectomy at the Department of Surgery, Yonsei University College of Medicine, during the period between Jan. 1987 and Dec. 1993. Among them, 130 patients had gastric carcinoma with extracellular mucin (MGC) and 1988 patients had gastric carcinoma without extracellular mucin (NMGC). We placed the MGC patients into two groups according to mucin content: mucin content involving over 50% of the tumor (dominant type, n = 94) and mucin content involving less than 50% of the tumor area (partial type, n = 36). The results were as follows: MGC was more common in males than NMGC. The size of the tumor in MGC (mean 5.3 cm) was larger than that of NMGC (mean 4.4 cm). The patients with MGC had a higher incidence of Borrmann type IV (MGC: 16.1%, NMGC: 9.9%), more frequent serosal invasion (MGC: 75.4%, NMGC: 48.6%), lymph-node metastasis (MGC: 75.4%, NMGC: 50.7%), and peritoneal metastasis (MGC: 10.0%, NMGC: 3.5%) than patients with NMGC. The patients with MGC were more advanced in stage at the time of diagnosis and had a worse overall 10-year survival rate (44.9%) than patients with NMGC (54.7%). However, the 10-year survival rate according to the stage of MGC was similar to that of NMGC. There were no significant differences between the mucin content and other pathologic variables, including prognosis, i.e. similar biologic behavior between dominant type MGC and partial type MGC. In conclusion, we suggest that MGC was more frequently diagnosed in advanced stage than NMGC with a poorer prognosis and that it is reasonable to consider the carcinoma with mucin content involving more than 30% of the tumor area as MGC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10333711     DOI: 10.3349/ymj.1999.40.2.99

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  6 in total

1.  Clinicopathologic features and prognosis analysis of mucinous gastric carcinoma.

Authors:  Chunming Yin; Deming Li; Zhe Sun; Ting Zhang; Yan Xu; Zhenning Wang; Huimian Xu
Journal:  Med Oncol       Date:  2011-02-05       Impact factor: 3.064

2.  Characteristics and prognosis of mucinous gastric carcinoma.

Authors:  Taro Isobe; Kousuke Hashimoto; Junya Kizaki; Satoru Matono; Naotaka Murakami; Tetsushi Kinugasa; Keishiro Aoyagi; Yoshito Akagi
Journal:  Mol Clin Oncol       Date:  2014-10-22

3.  Effect of extramucin pools in gastric cancer patients.

Authors:  Ki-Hyun Kim; Si-Hak Lee; Cheol-Woong Choi; Su-Jin Kim; Chang-In Choi; Dae-Hwan Kim; Tae-Yong Jeon; Dong-Heon Kim; Sun-Hwi Hwang
Journal:  Ann Surg Treat Res       Date:  2015-10-28       Impact factor: 1.859

4.  The Clinicopathological Features and Long-Term Survival Outcomes of Mucinous Gastric Carcinoma: a Consecutive Series of 244 Cases from a Single Institute.

Authors:  Xiaolong Tang; Jianwei Zhang; Xu Che; Zhongmin Lan; Yingtai Chen; Chengfeng Wang
Journal:  J Gastrointest Surg       Date:  2016-01-05       Impact factor: 3.452

5.  Prognosis of early mucinous gastric carcinoma.

Authors:  Seong Yeob Ryu; Ho Gun Kim; Jae Hyuk Lee; Dong Yi Kim
Journal:  Ann Surg Treat Res       Date:  2014-06-24       Impact factor: 1.859

6.  Mucin secretion activity of gastric cancer as a prognostic factor: a clinicopathological analysis.

Authors:  Joanna Huszno; Izolda Mrochen-Domin; Ewa Zembala-Nożyńska; Andrzej Tukiendorf; Dariusz Lange; Elżbieta Nowara
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.